RevolutionLogo.png
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
March 09, 2022 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
MooreKuehn.jpg
Moore Kuehn Encourages TGNA, MTOR, HMHC, and TEN Investors to Contact Law Firm
February 24, 2022 11:34 ET | Moore Kuehn
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
BES_Mark.jpg
MERITOR ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of MTOR and Encourages Investors to Contact the Firm
February 22, 2022 15:19 ET | Bragar Eagel & Squire
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
RevolutionLogo.png
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 10, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
April 21, 2021 07:00 ET | Revolution Medicines, Inc.
First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development Newly Issued U.S. Patent Further Strengthens RMC-5552 IP Portfolio REDWOOD CITY, Calif., April 21, 2021 (GLOBE...
RevolutionLogo.png
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 11, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
RevolutionLogo.png
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
March 02, 2021 16:05 ET | Revolution Medicines, Inc.
Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development Continued Progress in Development of RAS Companion Inhibitors to Support Targeted Combination...
RevolutionLogo.png
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
April 29, 2020 08:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
March 18, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
March 09, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...